- ￥490 - 2390
- Solarbio
- 北京
- IC2520
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:-20℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:-20℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
Cediranib Maleate
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
857036-77-2
- 规格：
50mg/25mg/10mg/5mg
| 规格： | 50mg | 产品价格： | ￥2390.0 |
|---|---|---|---|
| 规格： | 25mg | 产品价格： | ￥1490.0 |
| 规格： | 10mg | 产品价格： | ￥740.0 |
| 规格： | 5mg | 产品价格： | ￥490.0 |
| 基本信息 | |
| CAS | No.857036-77-2 |
| 中文名称 | 西地尼布马来酸盐 |
| 英文名称 | Cediranib Maleate |
| 别名 | AZD-2171 maleate |
| 分子式 | C25H27FN4O3·C4H4O4 |
| 分子量 | 566.58 |
| 溶解性 | Soluble in DMSO ≥5mg/mL(Need ultrasonic) |
| 纯度 | ≥98% |
| 外观(性状) | White to off-white Solid |
| 储存条件 | Powder:-20℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| SMILES | O=C(O)/C=C\C(O)=O.FC1=C(OC2=C(C(C=C3OCCCN4CCCC4)=NC=N2)C=C3OC)C=CC5=C1C=C(C)N5 |
| 靶点 | VEGFR |
| 通路 | Angiogenesis;Protein Tyrosine Kinase/RTK |
| 背景说明 | 是高选择性的 VEGFR2 抑制剂。 |
| 生物活性 | Cediranib maleate (AZD-2171 maleate) is a highly potent， orally available VEGFR inhibitor with IC50s of PDGFRα， PDGFRβ， c-Kit， respectively.[1] |
| In Vitro | In human umbilical vein endothelial cells， Cediranib inhibits VEGF-stimulated proliferation and KDR phosphorylation with IC50 values of 0.4 and 0.5 nM， respectively. In a fibroblast/endothelial cell coculture model of vessel sprouting， Cediranib also reduces vessel area， length， and branching at subnanomolar concentrations[1]. |
| 细胞实验 | Once-daily oral administration of Cediranib ablates experimental (VEGF-induced) angiogenesis and inhibits endochondral ossification in bone or corpora luteal development in ovary; physiologic processes that are highly dependent upon neovascularization. The growth of established human tumor xenografts (colon， lung， prostate， breast， and ovary) in athymic mice is inhibited dose-dependently by Cediranib， with chronic administration of 1.5 mg per kg per day producing statistically significant inhibition in all models. A histologic analysis of Calu-6 lung tumors treated with Cediranib reveals a reduction in microvessel density within 52 hours that becomes progressively greater with the duration of treatment. These changes are indicative of vascular regression within tumors[1]. |
| 细胞实验 | Proliferation of MG63 osteosarcoma cells is induced by PDGF-AA， which selectively activates PDGFR-α homodimer signaling. Cells are cultured in DMEM without phenol red containing 1% charcoal stripped FCS， 2 mM glutamine， and 1% nonessential amino acids for 24 hours. Cediranib or vehicle is added with PDGF-AA ligand (50 ng/mL) and plates reincubated for 72 hours. Cellular proliferation is determined using a bromodeoxyuridine[1]. |
| 动物实验 | Rats: Young female Alderley Park rats (6 weeks of age， Wistar derived， n=5) are dosed orally， once daily for 28 days with Cediranib (1.25-5 mg per kg per day) or vehicle. Additional rats (five per group) are treated with Cediranib (5 mg per kg per day) or vehicle for 28 days and maintained for a further 28 days without treatment， to examine the effect of compound withdrawal. Histologic paraffin wax sections of the femorotibial joints and ovaries are stained with H&E. Morphometric image analysis of femorotibial sections is done， with growth plate areas from both the femur and tibia in each joint being combined for an analysis of the effect of compound treatment. The area of corpora lutea in H&E-stained ovary sections is similarly determined by morphometric analysis[1]. |
| 激酶实验 | The inhibitory activity of Cediranib is determined against a range of recombinant tyrosine kinases [KDR， Flt-1， Flt-4， c-Kit， PDGFR-α， PDGFR-β， CSF-1R， Flt-3， FGFR1， Src， Abl， epidermal growth factor receptor (EGFR)， ErbB2， Aur-A， and Aur-B] using ELISA methodology[1]. |
| 数据来源文献 | [1]. Wedge SR， et al. AZD2171: a highly potent， orally bioavailable， vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res， 2005， 65(10)， 4389-4400. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验一氧化氮（ NO ）信号通路研究一氧化氮合酶（ NOS ）抑制剂研究背景：一氧化氮（ NO ）是自分泌和旁分泌的信号通路分子，可以扩散进入生物膜。发挥作用时间很短（几秒钟），主要的生理功能是促进血管动态平衡。它能够抑制平滑肌收缩生长，阻止血小板凝聚以及防止白细胞 - 内皮细胞粘附。另外它还参与免疫防御系统，神经传递，血管生成等过程。 NO 的下游靶标包括鸟苷酸环化酶和 NF-κB ，前者可以提高 cGMP 水平，后者在 iNOS 基因
.0 Aurintricarboxylic Acid 189400 抑制多种因子造成的不同类型细胞凋亡；DNA拓扑异构酶II的有效抑制剂；促进MAPK、Shc蛋白、PI 3激酶和PLC-g的酪氨酸磷酸化；有效抑制血管生成，增加angiostatic steroid活性；并可抑制calpain的两种亚型（m-calpain
细 胞 （T Cell s） 刺激骨 髓 （bone marrow）干细 胞 （stem Cell s） IL-4 辅助型 T细胞 （TH2-cells）, just activated naive CD4+ cell , memory C D4+ cells 参与扩散的B细胞和发展的T细胞和肥大细胞. Important role in allerg ic response
技术资料暂无技术资料 索取技术资料
